S21.F S2MEDICAL AB B
- Market cap
- EUR 250K
- P/E
- -
- P/B
- 0.27x
- ROE
- 7.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is S21.F undervalued?
Graham numberThe Graham number of S2MEDICAL AB B cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
S2MEDICAL AB B fundamental analysis
No fundamental analysis for S2MEDICAL AB B yet.
S2MEDICAL AB B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About S2MEDICAL AB B
S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and Epiprotect, a technology designed to protect and support wound healing by creat…
Full company profileS2MEDICAL AB B financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
S2MEDICAL AB B annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 7.70M | 4.67M | 6.97M | 14.7M | 14.4M | 29.7M |
| Gross Profit | 7.10M | 5.17M | 5.04M | 13.9M | 14.0M | 27.4M |
| Operating Income | -19.8M | -27.7M | -15.3M | 4.83M | -2.66M | 752K |
| EBITDA | - | -25.8M | -13.5M | 6.14M | -8.81M | 2.95M |
| Net Income | -20.1M | -29.5M | -22.7M | 4.81M | -10.1M | 744K |
| EPS | -0.27 | -0.19 | -0.05 | 0.00 | -0.01 | 0.00 |
| Balance Sheet | ||||||
| Total Assets | 29.7M | 25.3M | 21.4M | 25.4M | 16.9M | 16.9M |
| Total Liabilities | 15.0M | 18.2M | 19.7M | 6.64M | 7.03M | 6.84M |
| Shareholders' Equity | 14.7M | 7.07M | 1.66M | 18.7M | 9.87M | 10.1M |
| Cash & Short-term Investments | 9.48M | 3.72M | 1.52M | 1.00M | 907K | 564K |
| Cash Flow | ||||||
| Operating Cash Flow | -19.7M | -28.2M | -16.5M | 5.03M | 676K | 676K |
| Capital Expenditure | 3.10M | 1.90M | 1.15M | 634K | 2.02M | 2.05M |
| Free Cash Flow | -22.8M | -30.1M | -17.7M | 5.03M | -1.35M | -1.37M |
| Ratios | ||||||
| ROE | -136.8% | -416.7% | -1,369.6% | 25.7% | -102.2% | 7.4% |
| ROA | -67.7% | -116.5% | -106.1% | 19.0% | -59.7% | 4.4% |
| Net Profit Margin | -260.8% | -630.7% | -325.7% | 32.8% | -70.3% | 2.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
S2MEDICAL AB B dividends
S2MEDICAL AB B has not paid dividends in the last 5 fiscal years.
Who owns S2MEDICAL AB B
- Insiders 31.17%
- Institutions 10.07%
- Public & others 58.76%
- Shares outstanding 1.21B
- Free float 836M
S2MEDICAL AB B company profile
- Company name
- S2MEDICAL AB B
- Ticker
- S21.F
- ISIN
- SE0011725084
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 10
- Fiscal year end
- December
- Address
- Sunnorpsgatan 5, Linköping, Sweden, 582 73
- Phone
- 46 87 00 00 50
- Website
- s2m.se
About S2MEDICAL AB B
S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and Epiprotect, a technology designed to protect and support wound healing by creating an environment for tissue recovery. It also provides Symbiovance, a peptide-based functional skincare; Eyracure, a light-activated peptide technology that repairs damaged hair at the molecular level; and Eiratex, a biosynthetic polymer for wound healing applications. In addition, the company distributes instaQrett; skin substitutes under the EPIPROTECT brand; and BIOPAD, an ivory-white soft sponge. The company was incorporated in 2013 and is headquartered in Linköping, Sweden.
S2MEDICAL AB B management
2- Mr. Petter SivlerCo-Founder & CEO · born 1985
- Mr. Marten SkogCo-Founder, COO & Director · born 1982